What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 5.5% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices.
The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
The shares closed the day at $762.38, up 5% from previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock dropped 3.1% as the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment, Zepbound.
The study was evaluating bimagrumab in combination with Zepbound for obese or overweight adults with type 2 diabetes. Eli Lilly stated the trial was stopped for “strategic business reasons” just weeks after it had begun. The drug was designed to address a common side effect of rapid weight loss, which is the reduction of muscle mass. While the company confirmed that a separate study of bimagrumab in obese patients without diabetes would continue, the sudden termination of this key trial appeared to worry investors.
Eli Lilly is down 2% since the beginning of the year, and at $762.25 per share, it is trading 18.2% below its 52-week high of $932.06 from October 2024. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $5,150.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
